“Rogue” stem cell clinics exploit hope: report

By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) - Rogue clinics around the world may be exploiting hope and ignorance by offering unproven stem cell therapies, a group of stem cell experts said in a report released on Wednesday.

The International Society for Stem Cell Research released guidelines for researchers and regulators, and a guidebook for patients, that criticized some clinics.

“The International Society for Stem Cell Research is very concerned that stem cell therapies are being sold around the world before they have been proven safe and effective,” the guidelines said.

The group has declined to name any specific website or clinic but said they are widely advertised and reviewed in a study published in the journal Cell Stem Cell.

“The direct-to-consumer portrayal of stem cell medicine is optimistic and unsupported by published evidence,” Timothy Caulfield of the University of Alberta and colleagues wrote.

“The average cost of a course of therapy among the four websites that mentioned costs was $21,500, excluding travel and accommodation for patients and care givers. And examples of serious treatment side effects can be found.”

Stem cells are the body’s master cells and they come in a wide range of forms, from the cells in bone marrow that are widely used to treat cancer and other conditions, to embryonic stem cells — those that give rise to all the cell types in the body.

The field has received intense attention, in part because it carries the promise of tailored treatments and truly regenerative medicine that might transform treatment of diseases such as Parkinson’s, as well as catastrophic injuries.

It has also been sullied by scandal, notably the case of disgraced South Korean researcher Hwang Woo-suk, who admitted in 2006 to fabricating data to support claims he had made the first human embryos using cloning technology and then derived stem cells from them.

“Stem cell therapies are nearly all new and experimental. In these early stages, they may not work, and there may be downsides. Make sure you understand what to look out for before considering a stem cell therapy,” advises the patient advisory, available here

For researchers and regulators, the group advises tough oversight and independent review.

The group, including Dr. Marina Cavazzana-Calvo of Hopital Necker-Enfants Malades in Paris, France, Dr. Giulio Cossu of Instituto San Raffaele in Italy and Dr. George Daley of Children’s Hospital Boston, urged governments and regulatory bodies to enact the recommendations.

“Regulators have a responsibility to prevent exploitation of patients in their jurisdictions, and where necessary, to close fraudulent clinics and take disciplinary action against the doctors involved,” Daley said in a statement.

(Editing by Vicki Allen)


Related Posts:

By Esha Dey BANGALORE (Reuters) - Shares of companies developing therapies based on stem cells surged on Monday, after confirmation over the weekend that U.S. president-elect Barack Obama plans to reverse an existing executive order against federal funding of embryonic stem-cell research. Companies such as Geron Corp and StemCells Inc saw a sharp rise in their stock

Full Post: Stem-cell firms surge as Obama fuels funding hopes

LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes. An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by

Full Post: European agency rules against stem cell patents

By Ben Hirschler LONDON (Reuters) - A British biotechnology company, working with a team of doctors in Scotland, is to launch a pioneering clinical trial to assess whether stem cell therapy can help patients left disabled by stroke. ReNeuron Group Plc said on Sunday it had received approval from the UK Medicines and Healthcare Products Regulatory Agency

Full Post: UK firm to launch pioneering stem cell trial

By Ben Hirschler LONDON (Reuters) - Danish drugmaker Novo Nordisk A/S is turning to stem cells in the hunt for a cure for diabetes. The world leader in diabetes care said on Thursday it had launched a new collaboration to develop a treatment for type 1 diabetes by programing stem cells to turn into insulin-producing cells. The alliance

Full Post: Novo taps stem cells in hunt for diabetes cure

By Michael Kahn LONDON (Reuters) - A novel drug combination using Genzyme Corp’s Mozobil shows it may be possible to spur bone marrow into releasing extra adult stem cells into the bloodstream to repair the heart and broken bones, researchers said on Thursday. The study of mice raises hope that researchers could use the same technique to

Full Post: New drug combo may boost stem cell production

Site Navigation

Most Read



  • kinwrite.com@gmail.com